SMXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SMXT is not a good buy right now. The chart is only mildly constructive (positive MACD, neutral RSI), but there are no Intellectia buy signals, no news/catalysts, and the latest quarter shows sharply weaker profitability (very low gross margin and ongoing losses) despite big revenue growth. For an impatient buyer, the risk/reward is not compelling at the current ~$0.92 level unless it can break and hold above ~$1.00 with momentum.
Price/Trend: SMXT is trading around $0.924, slightly above the pivot support zone (Pivot ~$0.876). Trend reads as stabilizing/early-uptick rather than a strong uptrend. Momentum: MACD histogram is positive (0.00893) and expanding, which is supportive for near-term upside. RSI(6) ~54.6 is neutral (no clear overbought/oversold edge). Moving averages: Converging MAs suggest consolidation and a potential inflection, but not a confirmed trend. Key levels: Support S1 ~$0.751 (then S2 ~$0.674). Resistance R1 ~$1.001 (near-term breakout line), then R2 ~$1.078. Pattern-based forward bias: Similar-pattern study suggests modest upside probabilities (+0.06% next day, +4.31% next week, +10.99% next month), but not strong enough to override weak fundamentals.
Intellectia Proprietary Trading Signals
Technical momentum improving: positive and expanding MACD could support a short-term push toward ~$1.
Revenue growth: 2025/Q3 revenue rose sharply (+383.33% YoY), which can help sentiment if margins recover.
Pre-market strength: +2.59% pre-market move may indicate short-term speculative interest.
Profitability deterioration: 2025/Q3 gross margin collapsed to ~3.12% (down ~84.29% YoY), limiting the quality of revenue growth.
Continued losses: Net income -$2.26M and EPS -0.04 show the business is not currently translating growth into earnings.
No near-term catalysts: No news in the last week, and hedge fund/insider activity is neutral.
No supportive trading signals: Neither AI Stock Picker nor SwingMax is issuing a buy signal now, reducing confidence for an impatient entry.
No political/influential flow support: No recent Congress trading data available (last 90 days).
Latest quarter: 2025/Q3. Revenue: $30.60M, up +383.33% YoY (strong top-line growth). Profitability: Net income -$2.26M (down -76.53% YoY), EPS -0.04 (down -80.95% YoY). Margins: Gross margin ~3.12 (down -84.29% YoY), indicating severe margin compression. Overall: Growth is strong, but the quality of that growth is poor due to collapsing margins and deeper losses—this weakens the case for buying now.
No analyst rating or price target change data was provided, so Wall Street pros/cons cannot be confirmed from the dataset. Based on available information only: pros would point to explosive revenue growth and improving short-term momentum; cons would focus on very weak margins, ongoing losses, and lack of clear catalysts or institutional/insider conviction.
